Melanoma in situ : Part II. Histopathology, treatment, and clinical management - 15/07/15
, Kachiu C. Lee, MD, MPH a, Anjela Galan, MD c, David J. Leffell, MD bAbstract |
Melanoma in situ (MIS) poses special challenges with regard to histopathology, treatment, and clinical management. The negligible mortality and normal life expectancy associated with patients with MIS should guide treatment for this tumor. Similarly, the approach to treatment should take into account the potential for MIS to transform into invasive melanoma, which has a significant impact on morbidity and mortality. Part II of this continuing medical education article reviews the histologic features, treatment, and management of MIS.
Le texte complet de cet article est disponible en PDF.Key words : lentigo maligna, melanoma, melanoma in situ
Abbreviations used : IHC, MIS, LM, MM, MMS, SEER, WLE
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Date of release: August 2015 |
|
| Expiration date: August 2018 |
Vol 73 - N° 2
P. 193-203 - août 2015 Retour au numéro
Article précédent
- American Board of Dermatology Examination Dates
- Answers to CME examination
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?